Datapoint: UCB Snags Fintepla Expansion

Belgian biopharma company UCB scored an expanded label for its drug Fintepla. The FDA this week approved Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy, in patients 2 and older. The drug will have to face off against Jazz Pharmaceuticals groundbreaking cannabinoid Epidiolex, which was first approved for Lennox-Gastaut in 2018. For the treatment of epilepsy, Fintepla and Epidiolex are covered at parity for 71.8% of all insured lives.

SOURCE: MMIT Analytics, as of 3/28/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: HealthPartners to Launch Insurance Products With Avera

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today